Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>Conclusion:</i> The methylation analysis of the SHOX2 and RASSF1A panel in BALF with RT-PCR achieved a satisfactory sensitivity and specificity in lung cancer diagnosis, especially in an early stage.
|
29151944 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A, a recently identified candidate tumor suppressor gene, was found to be inactivated in lung cancer and other tumor types.
|
14506151 |
2003 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A is one of the tumor suppressor genes, and it is frequently inactivated by hypermethylation of its promoter region in a variety of human cancers, including lung cancer.
|
15700308 |
2005 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A is validated as diagnostic marker in lung cancer.
|
25719833 |
2015 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A, a tumor suppressor gene, is frequently inactivated in lung cancer leading to a YAP-dependent epithelial-mesenchymal transition (EMT).
|
30979377 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A cross-sectional study was conducted in which the methylation status of DAPK, CDKN2A (p16) and RASSF1A genes in sputum and bronchial washing (BW) from subjects at risk for LC was analyzed.
|
25069886 |
2014 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
CTD_human |
DNA methylation markers and early recurrence in stage I lung cancer.
|
18337602 |
2008 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, a significant correlation between RASSF1A methylation and impaired lung cancer patient survival was reported, and RASSF1A silencing was correlated with several parameters of poor prognosis and advanced tumor stage (e.g. poor differentiation, aggressiveness, and invasion).
|
12647816 |
2003 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
FUS1, NPRL2/G21 and RASSF1A are TSGs from LUCA region at 3p21.3, a critical chromosomal region in lung cancer development.
|
26112163 |
2015 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
However, the sensitivity analysis indicated that RASSF1A methylation from lung cancer tissues was significantly associated with lower OS (HR = 1.24; 95% CI 1.04-1.45).
|
30764677 |
2019 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Importantly, knockdown of DNMT1 by siRNA <i>in vivo</i> also effectively demethylated the RASSF1A and APC promoter, elevated their expressions and limited tumor growth, which functioned like 5-Aza-CR but with alleviated side effects, suggesting that knockdown of DNMT1 might be potential strategy for the treatment of lung cancer with better tolerability.
|
28938637 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, perturbation of the ATR-RASSF1A-LATS1 signalling axis leads to genomic defects associated with loss of BRCA2 function and contributes to genomic instability and 'BRCA-ness' in lung cancers.
|
25218637 |
2014 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In lung cancer cell lines, CpG island methylation was frequently detected for TIMP4 (64%), SOX18 (73%), EGF-like domain 7 (56%), CD105 (71%), SEMA2 (55%), RASSF1A (71%), p16 (56%) SLIT2 (100%) and TIMP3 (29%).
|
15911247 |
2005 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, the diagnostic utility of the SHOX2 assay was tested with regard to cytology for different cytological diagnostic categories to assess whether it can complement the cytological examination and the DNA methylation marker panel targeting the gene promoters of adenomatous polyposis coli 1A (APC), cyclin-dependent kinase inhibitor-2A (p16(INK4A)) and Ras association domain family protein 1 (RASSF1A) regarding lung cancer detection in bronchial aspirates.
|
25331797 |
2015 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we show that RASSF1A inhibits the growth of lung cancer cells by blocking the JNK pathway.
|
15867363 |
2005 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Inactivation of the tumor suppressor gene RASSF1A by promoter hypermethylation represents a key event underlying the initiation and progression of lung cancer.
|
26759237 |
2016 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of DeltaDNMT3B4 expression by small interfering RNA resulted in a rapid demethylation of RASSF1A promoter and reexpression of RASSF1A mRNA but had no effect on p16 promoter in the lung cancer cells.
|
18006804 |
2007 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
L1RE1 in combination with either RARB or RASSF1 could function as biomarkers for separating lung cancer and non-cancerous tissue and could be useful for samples of limited size such as biopsies.
|
29851970 |
2018 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Our findings suggest that RASSF1A promoter region hypermethylation may be a useful molecular marker for early detection of lung cancer.
|
12527916 |
2003 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic value in early lung cancer detection.
|
16152615 |
2006 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Overall, a significant relationship between RASSF1A promoter methylation and lung cancer risk (OR, 16.12; 95%CI, 11.40-22.81; p<0.001) with no between-study heterogeneity.
|
25556469 |
2014 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pathway analysis revealed that target genes of RASSF1 and KRAS play roles as oncogene or tumor suppressor gene in the progression of lung cancer.
|
23771539 |
2013 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previously, the RASSF1A, BLU and SEMAPHORIN 3B (SEMA3B) candidate tumor suppressor genes on chromosome 3p21.3 were found to be inactivated and downregulated by genetic and epigenetic changes in lung cancer.
|
15704097 |
2005 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
|
17606310 |
2007 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
PubMed, EBSCO, Ovid, Wiley, Web of Science, Wanfang, and VIP databases were searched using combinations of keywords related to RASSF1A, p16, methylation, and lung cancers.
|
27072261 |
2016 |